Pharmacokinetics and intrapulmonary diffusion of levofloxacin in critically ill patients with severe community-acquired pneumonia
- 1 January 2005
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Critical Care Medicine
- Vol. 33 (1) , 104-109
- https://doi.org/10.1097/01.ccm.0000150265.42067.4c
Abstract
To determine the steady-state plasma and epithelial lining fluid concentrations of intravenous levofloxacin, 500 mg, administered once or twice daily in critically ill patients with severe community-acquired pneumonia. Prospective, open-label study. An intensive care unit and a clinical pharmacokinetic laboratory in two university hospitals. Twenty-four adult patients with severe community-acquired pneumonia and receiving mechanical ventilation were enrolled. All subjects received 1-hr intravenous infusions of 500 mg levofloxacin once or twice daily. The plasma and epithelial lining fluid levofloxacin concentrations were determined at steady-state after 2 days of therapy with high-performance liquid chromatography. The median (interquartile range [IQR]) plasma and epithelial lining fluid peak levofloxacin concentrations were 12.6 (IQR, 12.0-14.1) and 11.9 (IQR, 8.7-13.7) mg/L, respectively, in the once-daily group and 19.7 (IQR, 19.0-22.0) and 17.8 (IQR, 16.2-23.5) mg/L in the twice-daily group, showing a pulmonary percentage penetration of >100% in both groups. The median (IQR) total body exposures were 151 (IQR, 137-174) and 416 (IQR, 406-472) mg.hr/L, respectively, in the once-daily and twice-daily groups. Our results suggest that in critically ill patients who are receiving mechanical ventilation and have severe community-acquired pneumonia and creatinine clearance of >40 mL/min, the administration of 500 mg of intravenous levofloxacin once and twice daily allows for the exceeding of pharmacodynamic thresholds predictive of outcome (i.e., peak concentration to minimum inhibitory concentration ratio of >10 or area under concentration-time curve to minimal inhibitory concentration ratio of >125 hrs) both in serum and epithelial lining fluid for pathogens with minimum inhibitory concentration values of < or =1 mg/L and >1 mg/L, respectively.Keywords
This publication has 33 references indexed in Scilit:
- Guidelines for Empiric Antimicrobial Prescribing in Community-Acquired PneumoniaChest, 2004
- Community-acquired pneumoniaCurrent Opinion in Pulmonary Medicine, 2003
- Pharmacokinetics and Pharmacodynamics of Intravenous Levofloxacin in Patients with Early-Onset Ventilator-Associated PneumoniaClinical Pharmacokinetics, 2003
- Guidelines for the Management of Adults with Community-acquired PneumoniaAmerican Journal of Respiratory and Critical Care Medicine, 2001
- Community‐Acquired Pneumonia in Adults: Guidelines for ManagementClinical Infectious Diseases, 1998
- Pharmacodynamics of LevofloxacinJAMA, 1998
- The Clinical Pharmacokinetics of LevofloxacinClinical Pharmacokinetics, 1997
- Community-Acquired PneumoniaNew England Journal of Medicine, 1995
- New Concepts in the Pulmonary Disposition of AntibioticsPulmonary Pharmacology, 1995
- The site concentrations of antimicrobial agents in the lungJournal of Antimicrobial Chemotherapy, 1992